17,17'- bis(cyclopropylmethyl)- 6,6',7,7'- tetrahydro- 4,5- 4',5'- diepoxy- 6,6'- (benzylimino)(7,7'- bimorphinan)- 3,3',14,14'- tetrol
functions short-term as an MOR agonist and long-term as an KOR antagonist; structure in first source
Also Known As:
N-benzyl-norBNI
Networked: 0
relevant articles (0 outcomes,
0 trials/studies)
Bio-Agent Context: Research Results
- Heterocyclic Compounds: 198
- Alkaloids: 5398
- Opiate Alkaloids: 5944
- Morphinans: 33
- Naloxone: 5958
- Naltrexone: 2720
- 17,17'-bis(cyclopropylmethyl)-6,6',7,7'-tetrahydro-4,5-4',5'-diepoxy-6,6'-(benzylimino)(7,7'-bimorphinan)-3,3',14,14'-tetrol
- Bridged-Ring Heterocyclic Compounds
- Morphinans: 33
- Naloxone: 5958
- Naltrexone: 2720
- 17,17'-bis(cyclopropylmethyl)-6,6',7,7'-tetrahydro-4,5-4',5'-diepoxy-6,6'-(benzylimino)(7,7'-bimorphinan)-3,3',14,14'-tetrol
- Fused-Ring Heterocyclic Compounds
- 4 or More Rings Heterocyclic Compounds
- Morphinans: 33
- Naloxone: 5958
- Naltrexone: 2720
- 17,17'-bis(cyclopropylmethyl)-6,6',7,7'-tetrahydro-4,5-4',5'-diepoxy-6,6'-(benzylimino)(7,7'-bimorphinan)-3,3',14,14'-tetrol
- Polycyclic Compounds: 6
- Polycyclic Aromatic Hydrocarbons: 2020
- Phenanthrenes: 27
- Morphinans: 33
- Naloxone: 5958
- Naltrexone: 2720
- 17,17'-bis(cyclopropylmethyl)-6,6',7,7'-tetrahydro-4,5-4',5'-diepoxy-6,6'-(benzylimino)(7,7'-bimorphinan)-3,3',14,14'-tetrol